|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
on1273413815 |
| 003 |
OCoLC |
| 005 |
20240909213021.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
211005s2021 sz a o 001 0 eng d |
| 040 |
|
|
|a GW5XE
|b eng
|e rda
|e pn
|c GW5XE
|d YDX
|d OCLCO
|d EBLCP
|d OCLCF
|d N$T
|d UKAHL
|d OCLCQ
|d COM
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|d OCLCQ
|
| 019 |
|
|
|a 1272956512
|a 1273076388
|a 1273121564
|
| 020 |
|
|
|a 9783030740283
|q (electronic bk.)
|
| 020 |
|
|
|a 3030740285
|q (electronic bk.)
|
| 020 |
|
|
|z 9783030740276
|
| 020 |
|
|
|z 3030740277
|
| 024 |
7 |
|
|a 10.1007/978-3-030-74028-3
|2 doi
|
| 035 |
|
|
|a (OCoLC)1273413815
|z (OCoLC)1272956512
|z (OCoLC)1273076388
|z (OCoLC)1273121564
|
| 050 |
|
4 |
|a RC280.L8
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Lung cancer :
|b new understandings and therapies /
|c Anne C. Chiang, Roy S. Herbst, editors.
|
| 264 |
|
1 |
|a Cham, Switzerland :
|b Springer,
|c 2021.
|
| 300 |
|
|
|a 1 online resource (vi, 264 pages) :
|b illustrations (some color)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Current cancer research,
|x 2199-2592
|
| 505 |
0 |
|
|a Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.
|
| 500 |
|
|
|a Includes index.
|
| 520 |
|
|
|a Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed October 5, 2021).
|
| 650 |
|
0 |
|a Lungs
|x Cancer.
|
| 650 |
|
0 |
|a Lungs
|x Cancer
|x Treatment.
|
| 650 |
|
7 |
|a Lungs
|x Cancer
|2 fast
|
| 650 |
|
7 |
|a Lungs
|x Cancer
|x Treatment
|2 fast
|
| 700 |
1 |
|
|a Chiang, Anne C.,
|e editor.
|
| 700 |
1 |
|
|a Herbst, Roy,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|z 9783030740283
|
| 776 |
0 |
8 |
|i Print version:
|z 3030740277
|z 9783030740276
|w (OCoLC)1241732686
|
| 830 |
|
0 |
|a Current cancer research,
|x 2199-2592
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-3-030-74028-3
|y Click for online access
|
| 903 |
|
|
|a SPRING-MED2021
|
| 994 |
|
|
|a 92
|b HCD
|